Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use

By Hoffman S.L.   Doolan D.L.   Sedegah M.   Aguiar J.C.   Wang R.   Malik A.   Gramzinski R.A.   Weiss W.R.   Hobart P.   Norman J.A.   Margalith M.   Hedstrom R.C.  

Vaccine, Vol. 15, Iss. 8, 1997-06 ,pp. : 842-845

Elsevier

Access to resources Recommend Favorite

Immunogenicity of chimeric multiple antigen peptides based on Plasmodium falciparum antigens: impact of epitope orientation

By Ahlborg N.   Nardin E.H.   Perlmann P.   Berzins K.   Andersson R.  

Vaccine, Vol. 16, Iss. 1, 1998-01 ,pp. : 38-44

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

By Genton B.   Al-Yaman F.   Betuela I.   Anders R.F.   Saul A.   Baea K.   Mellombo M.   Taraika J.   Brown G.V.   Pye D.   Irving D.O.   Felger I.   Beck H.-P.   Smith T.A.   Alpers M.P.  

Vaccine, Vol. 22, Iss. 1, 2003-12 ,pp. : 30-41

Elsevier

Access to resources Recommend Favorite

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21

By Kashala O.   Amador R.   Valero M.V.   Moreno A.   Barbosa A.   Nickel B.   Daubenberger C.A.   Guzman F.   Pluschke G.   Patarroyo M.E.  

Vaccine, Vol. 20, Iss. 17, 2002-05 ,pp. : 2263-2277

Elsevier

Access to resources Recommend Favorite

DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice

By Hanke T.   Schneider J.   Gilbert S.C.   Hill A.V.S.   McMichael A.  

Vaccine, Vol. 16, Iss. 4, 1998-02 ,pp. : 426-435

Elsevier

Access to resources Recommend Favorite